CUMYL-PEGACLONE (SGT-151) is a gamma-carboline based synthetic cannabinoid that has been sold as a designer drug. The gamma-carboline core structure seen in CUMYL-PEGACLONE had not previously been encountered in a designer cannabinoid, though it is similar in structure to other gamma-carboline cannabinoids disclosed by Bristol-Myers Squibb in 2001.

Legal status

Sweden's public health agency classified CUMYL-PEGACLONE as a narcotic substance, on January 18, 2019.

CUMYL-PEGACLONE

In the United States, the DEA has filed a notice for its intent to temporarily place CUMYL-PEGACLONE into Schedule I status starting on or after May 4th, 2023 for up to 2 years, during which it's possible the DEA could file for permanent scheduling within those 2 years. If it's filed on May 4, 2023, and the DEA does not file to permanent placement the temporary Schedule I order will expire on May 4, 2025.

CUMYL-PEGACLONE

See also

5F-CUMYL-PEGACLONE

CUMYL-CB-MEGACLONE

CUMYL-CH-MEGACLONE

CUMYL-BC-HPMEGACLONE-221

CUMYL-PINACA

CUMYL-5F-P7AICA

UR-12

References

Cannabinoids

Designer drugs

Gamma-Carbolines

CUMYL-PEGACLONE